Announcements
Sidley Represents Neomorph in Its US$100 Million Series B Financing
April 15, 2026
Sidley represented Neomorph, Inc., a biotechnology company developing innovative molecular glue degraders, in its US$100 million Series B financing. The round was led by Deerfield Management, with participation from new investors Regeneron Ventures, Longwood Fund, Alexandria Venture Investments, and Binney Street Capital. The proceeds from the financing will support Neomorph’s continued advancement of its proprietary platform and pipeline focused on discovering and developing molecular glue degraders targeting previously intractable diseases.
The Sidley team was led by Rosemary G. Reilly (Emerging Companies and Venture Capital) and included Rebecca Nauta (Emerging Companies and Venture Capital) and Matthew Dutton (Investment Funds).
連絡先
得意分野
Suggested News & Insights
Sidley, Innovation Endeavors, and Premji Happy Hour Reception at JPMTuesday, January 12, 2027Recharge & Recaffeinate With Sidley @ JPMMonday, January 11, 2027 – Tuesday, January 12, 2027Sidley Represents Hanmi Pharm and Green Cross Biopharma in Licensing Agreement With BioMarinOctober 30, 2026Introducing SidleyCatalyst: Built to Accelerate GrowthOctober 28, 2026Sidley Represents Bolt Biotherapeutics in the Acquisition of Prana Therapies and Concurrent US$120 Million Private Placement FinancingOctober 26, 2026Sidley Represents ZAP Surgical as It Secures US$36 Million in FinancingOctober 22, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory


